A potential cancer drug aimed at enhancing the effectiveness of ionizing radiation in lung cancer patients is a step closer to development with funding support from the Small Business Innovation Research (SBIR) program.
News: September, 2018
A trans-institutional team of researchers at Vanderbilt University Medical Center and Vanderbilt University has received an $11 million Cancer Moonshot grant to build a single-cell resolution atlas to map out the routes that benign colonic polyps take to progress to colorectal cancer.
A drug commonly used to treat type 2 diabetes might help prevent patients from developing liver cancers, according to a recent study by Harvey J. Murff, MD, MPH, and colleagues.
The T.J. Martell Foundation’s 6th Annual Chic Awearness fundraising event that supports ovarian cancer research at Vanderbilt-Ingram Cancer Center (VICC) will be held Monday, Sept. 24, 6:30 – 8:30 p.m., at Analog at the Hutton Hotel, 1808 West End Ave.
Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Vanderbilt investigators have conducted a prospective multicenter study on how extracorporeal photopheresis works in treating chronic graft-versus-host disease (cGVHD) — a complication of bone marrow or stem cell transplant that occurs when donor cells attack the recipient.
Vanderbilt researchers have identified a previously undetected type of histone modification that may have implications for cancer and other conditions.
The Sonic hedgehog protein plays a crucial role in the development of brain cells that may be the source of some types of pediatric brain tumors, a recent study reports.